Thiogenesis Therapeutics, Corp. TTI.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · thiogenesis.com
Thiogenesis Therapeutics Corp. is a clinical-stage biopharmaceutical company headquartered in Toronto, Canada, developing thiol-based therapeutic compounds to treat unmet pediatric medical needs including inherited mitochondrial diseases. Its lead product candidate, TTI-0102, is a novel prodrug of cysteamine designed to reduce oxidative stress and restore mitochondrial function, with potential applications in MELAS, Leigh syndrome, and Rett syndrome.
Key ratios
ReturnOnAssets TTM -1.11
ReturnOnAssets 2024 -0.4
ReturnOnAssets 2023 -0.48
ReturnOnAssets 2022 -0.39
ReturnOnEquity TTM -2.17
ReturnOnEquity 2024 -0.7
ReturnOnEquity 2023 -0.88
ReturnOnEquity 2022 -1.59
Recent news
Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors
2026-06-17 · Newsfile Corp.
Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million
2026-06-03 · Newsfile Corp.
Thiogenesis Announces Non-Brokered Private Placement
2026-05-11 · Newsfile Corp.
Thiogenesis Therapeutics to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
2026-04-16 · Newsfile Corp.